Blank Bio
Foundation models that combine isoform, mutation, and expression signals from RNA to improve patient stratification and boost diagnostic accuracy for precision medicine
Blank Bio
Foundation models that combine isoform, mutation, and expression signals from RNA to improve patient stratification and boost diagnostic accuracy for precision medicine
Executive Summary
Blank Bio is a YC S25 seed-stage TechBio company building RNA foundation models that operate at transcript-level resolution — capturing isoform, mutation, and expression signals that most commercial tools discard. The founding team is genuinely exceptional for its stage: three PhD researchers with direct pedigree at Deep Genomics, Valence Labs, and Recursion, whose open-source model is reportedly adopted by Sanofi and GSK (self-reported, unconfirmed independently). The scientific thesis is sound and market timing is strong — RNA analysis and AI-driven precision medicine are two of the fastest-growing segments in biotech — but Blank Bio's biggest risk is the one it cannot technical-credential its way out of: an undefined business model, an open-source monetization trap, and pharma sales cycles that will outlast a typical seed runway.
Run your own diligence
Upload a pitch deck or paste any company URL to get a full AI-powered due diligence report in under 2 minutes.
Get started free →Free plan available · No credit card required